Precision Biosensor

프리시젼바이오 · 335810

Health Care Medical Devices · KOSDAQ

Small-cap

Market cap US$27.8M (₩38.4B)

Overview

Precision Biosensor makes portable, rapid diagnostic test devices and cartridges that detect disease markers, such as those for heart attacks, infectious diseases, and brain conditions, directly at the point of care, delivering results within minutes.

Its products are designed for use in hospitals and clinical settings, and it supplies both human and veterinary diagnostic instruments. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company's entire product portfolio is built around point-of-care testing, with its core platform using a time-resolved fluorescence imaging technology originally derived from satellite camera optics.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$14.4M

▲ +4.1% YoY

Operating profit · FY2025

−US$3.9M

Loss widened

Net income · FY2025

−US$7.3M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$14.8M(₩20.4B)	US$13.9M(₩19.1B)	US$14.4M(₩19.9B)
Operating profit	−US$3.5M(−₩4.8B)	−US$3.9M(−₩5.4B)	−US$3.9M(−₩5.4B)
Net income	−US$3.3M(−₩4.5B)	−US$5.3M(−₩7.3B)	−US$7.3M(−₩10B)

Revenue

FY2023US$14.8M
FY2024US$13.9M
FY2025US$14.4M

Operating profit

FY2023−US$3.5M
FY2024−US$3.9M
FY2025−US$3.9M

Net income

FY2023−US$3.3M
FY2024−US$5.3M
FY2025−US$7.3M

Key ratios (FY2025)

ROE

-30.6%

Debt/Eq

62.0%

Op. margin

-27.0%

Net margin

-50.3%

Rev. YoY

▲ +4.1%

Why it matters

The company holds Nano-Ditech, a US-based immunodiagnostic cartridge developer and manufacturer, as a wholly owned subsidiary.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?